Potential role of microRNAs as biomarkers in human glioblastoma: a mini systematic review from 2015 to 2020

M, Menezes; Acioli, Maria Eduarda Azevedo; Trindade, Ana Carolina Lemos da; Silva, Suéllen Pedrosa da; Lima, Raul Emídio de; Teixeira, Vanessa Gabryelle da Silva; Vasconcelos, Luydson Richardson Silva

doi:10.1007/s11033-021-06423-9

Cited by 6 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-125a and miR-125b could have a double role, because, in CSCs of hepatocellular carcinoma, they also inhibit cancer-associated macrophages, limiting tumor progression [112]. Importantly, the findings collected so far indicate that microRNAs, functioning as oncogenes or tumor suppressors, can be used as tumor biomarkers or therapeutic targets [294,295]. In some tumors, such as multiple myeloma, preliminary basic studies and associated clinical works have explored the value of microRNAs as potential biomarkers [296].…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

et al. 2021

View full text Add to dashboard Cite

Embryonic stem cells (ESCs) have the extraordinary properties to indefinitely proliferate and self-renew in culture to produce different cell progeny through differentiation. This latter process recapitulates embryonic development and requires rounds of the epithelial–mesenchymal transition (EMT). EMT is characterized by the loss of the epithelial features and the acquisition of the typical phenotype of the mesenchymal cells. In pathological conditions, EMT can confer stemness or stem-like phenotypes, playing a role in the tumorigenic process. Cancer stem cells (CSCs) represent a subpopulation, found in the tumor tissues, with stem-like properties such as uncontrolled proliferation, self-renewal, and ability to differentiate into different cell types. ESCs and CSCs share numerous features (pluripotency, self-renewal, expression of stemness genes, and acquisition of epithelial–mesenchymal features), and most of them are under the control of microRNAs (miRNAs). These small molecules have relevant roles during both embryogenesis and cancer development. The aim of this review was to recapitulate molecular mechanisms shared by ESCs and CSCs, with a special focus on the recently identified classes of microRNAs (noncanonical miRNAs, mirtrons, isomiRs, and competitive endogenous miRNAs) and their complex functions during embryogenesis and cancer development.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to the World Health Organization (WHO) grading, gliomas are categorized into four grades (I-IV) [5]. Among these four grades [6], glioblastoma multiforme (GBM; grade IV) is the most common, aggressive, and malignant form of glioma [7,8]. The main features of GBM are rapid proliferation with poor differentiation, diffuse infiltration into normal brain tissues, angiogenesis, tendency to necrosis, resistance to apoptosis, widespread genomic aberrations [8,9], and these features make GBM challenging to treat [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…Among these four grades [6], glioblastoma multiforme (GBM; grade IV) is the most common, aggressive, and malignant form of glioma [7,8]. The main features of GBM are rapid proliferation with poor differentiation, diffuse infiltration into normal brain tissues, angiogenesis, tendency to necrosis, resistance to apoptosis, widespread genomic aberrations [8,9], and these features make GBM challenging to treat [8][9][10][11]. Current treatment protocol involves surgical resection followed by concurrent radiotherapy and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months [1,8].…”

Section: Introductionmentioning

confidence: 99%

“…The main features of GBM are rapid proliferation with poor differentiation, diffuse infiltration into normal brain tissues, angiogenesis, tendency to necrosis, resistance to apoptosis, widespread genomic aberrations [8,9], and these features make GBM challenging to treat [8][9][10][11]. Current treatment protocol involves surgical resection followed by concurrent radiotherapy and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months [1,8]. Despite tremendous efforts devoted to improving the therapeutic strategies towards GBM, the prognosis for patients with GBM still remains poor [3] and the median survival rates of these patients are very low [8,9].…”

Section: Introductionmentioning

confidence: 99%

“…Current treatment protocol involves surgical resection followed by concurrent radiotherapy and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months [1,8]. Despite tremendous efforts devoted to improving the therapeutic strategies towards GBM, the prognosis for patients with GBM still remains poor [3] and the median survival rates of these patients are very low [8,9]. The risk of recurrence is high since current therapies do not take into account the unique molecular features of different subtypes of glioma [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy

Çi̇ftçi̇

Radwan

Sever

et al. 2021

IJMS

View full text Add to dashboard Cite

Glioma, particularly its most malignant form, glioblastoma multiforme (GBM), is the most common and aggressive malignant central nervous system tumor. The drawbacks of the current chemotherapy for GBM have aroused curiosity in the search for targeted therapies. Aberrantly overexpressed epidermal growth factor receptor (EGFR) in GBM results in poor prognosis, low survival rates, poor responses to therapy and recurrence, and therefore EGFR-targeted therapy stands out as a promising approach for the treatment of gliomas. In this context, a series of pentacyclic triterpene analogues were subjected to in vitro and in silico assays, which were conducted to assess their potency as EGFR-targeted anti-glioma agents. In particular, compound 10 was the most potent anti-glioma agent with an IC50 value of 5.82 µM towards U251 human glioblastoma cells. Taking into account its low cytotoxicity to peripheral blood mononuclear cells (PBMCs), compound 10 exerts selective antitumor action towards Jurkat human leukemic T-cells. This compound also induced apoptosis and inhibited EGFR with an IC50 value of 9.43 µM compared to erlotinib (IC50 = 0.06 µM). Based on in vitro and in silico data, compound 10 stands out as a potential orally bioavailable EGFR-targeted anti-glioma agent endowed with the ability to cross the blood–brain barrier (BBB).

show abstract

Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: Therapeutic challenges and opportunities

Subaiea,

Syed,

Afsar

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

Potential role of microRNAs as biomarkers in human glioblastoma: a mini systematic review from 2015 to 2020

Cited by 6 publications

References 55 publications

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

MicroRNAs and Stem-like Properties: The Complex Regulation Underlying Stemness Maintenance and Cancer Development

EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy

Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: Therapeutic challenges and opportunities

Contact Info

Product

Resources

About